Table 2 Baseline characteristics of included studies
| Â | HannaH 2015 | PrefHer 2017 | MetaspHer 2017 | |
|---|---|---|---|---|
| Â | Trastuzumab SC (n = 294) | Trastuzumab IV (n = 297) | n = 483 | n = 113 |
Design | RCT | Â | RCT, crossover | RCT, crossover |
Follow-up | 52–172 weeks |  | 24 weeks | 18 weeks |
Age (years) | 50 (25–81) | 50 (24–77) | 53 (27–83) | 59 (35–85) |
Body weight (kg) | 68 (39–126) | 66 (42–137) | 66 (41–117) | 70 (46–110) |
Breast cancer subtype | Â | Â | Â | |
Ductal | 272 (92.8%) | 273 (91.9%) | Not specified | 70 (87.5%) |
Lobular | 12 (4.1%) | 17 (5.7%) | Â | 3 (3.8%) |
Other | 9 (3.1%) | 7 (2.4%) | Â | 6 (7.5%) |
Ductal + other | 0 | 0 | Â | 1 (1.3%) |
Estrogen receptor status | Â | Â | Â | |
Negative | 140 (47.6%) | 148 (49.8%) | 168 (34.8%) | 43 (38.1%) |
Positive | 154 (52.4%) | 148 (49.8%) | 309 (64%) | 57 (50.4%) |
Unknown | 0 | 1 (0.3%) | 6 (1.2%) | 13 (11.5%) |
Nodal status | Â | Â | Â | |
Negative | 71a, b (24.2%) | 62a (20.9 %) | 229 (49.04%)c | Not specified |
Positive | 222a, b (75.8%) | 235a (88 %) | 227 (48.61%)c | Â |
Unknown | 0 | 0 | 11 (2.36%)c | Â |
Tumor stage | Â | Â | Â | |
T0 | 0 | 0 | 5 (1%) | Not specified |
T1 | 19 (6.5%)d | 23 (7.9%)d | 204 (42.2%) | Â |
T2 | 129 (44%)d | 130 (43.8%)d | 208 (43.1%) | Â |
T3 | 52 (17.7%)d | 49 (16.5%)d | 37 (7.7%) | Â |
T4 | 93 (31.7%)d | 95 (32%)d | 25 (5.2%) | Â |
Unknown | 0 | 0 | 4 (0.8%) | Â |